(Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis UTI Healthcare Fund - G
Scheme Objective
CAGR
return of 14.9% since its launch. Ranked 40 in Sectoral
category. Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% . NAV as on 10 Oct 25 ₹292.735 ↑ 2.54 (0.88 %) Net Assets (AUM) as on 31 Aug 2025 ₹1,119 Cr. Launch Date 28 Jun 1999 Category Equity - Sectoral Rating ☆ Type Open Ended Fund Risk High AMC UTI Asset Management Company Ltd Alpha Ratio 0.79 Expense Ratio 2.26 % Sharpe Ratio -0.149 Information Ratio 0.1 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 10 Oct 25 Duration Returns 1 Month -0.8% 3 Month 1.9% 6 Month 15.1% 1 Year 1.3% 3 Year 24.5% 5 Year 17.1% 10 Year 15 Year Since launch 14.9% Historical Annual Returns
Year Returns 2024 42.9% 2023 38.2% 2022 -12.3% 2021 19.1% 2020 67.4% 2019 1.2% 2018 -7.5% 2017 6.2% 2016 -9.7% Growth of 10k Over Years
Date Value Asset Allocation
Asset Class Value Cash 0.65% Equity 99.35% Sector Allocation
Sector Value Health Care 98.23% Basic Materials 1.12% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMADrug Manufacturers - Specialty & Generic 9% ₹105 Cr 661,016 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | CIPLADrug Manufacturers - Specialty & Generic 6% ₹64 Cr 400,000 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | AJANTPHARMDrug Manufacturers - Specialty & Generic 5% ₹60 Cr 242,673
↑ 42,673 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | LUPINDrug Manufacturers - Specialty & Generic 5% ₹51 Cr 270,000
↑ 15,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDYDrug Manufacturers - Specialty & Generic 4% ₹45 Cr 360,000 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHLDrug Manufacturers - Specialty & Generic 4% ₹45 Cr 70,039
↓ -10,244 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | FORTISMedical Care Facilities 4% ₹42 Cr 465,000 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | GLENMARKDrug Manufacturers - Specialty & Generic 4% ₹42 Cr 220,000
↑ 30,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSPMedical Care Facilities 4% ₹40 Cr 53,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEMDrug Manufacturers - Specialty & Generic 3% ₹38 Cr 72,000
↑ 17,000
Talk to our investment specialistFund Managers
Name Since Tenure Kamal Gada 2 May 22 3.34 Yr. Custodians
Company Address Axis Bank Ltd null Deutsche Bank AG MUMBAI Deitsche bank,Kodak House Stock Holding Corporation of India Mittal Court, ‘B’ Wing,,Nariman Point Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address UTI Asset Management Co Ltd PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051 Auditors
Company Address S. R. BATLIBOI & Co Express Tower, 6th Floor,Nariman Point,Mumbai All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year UTI Healthcare Fund
Growth ₹292.735
↑ 2.54 15.13 % 1.31 % 24.55 % 17.12 % UTI Healthcare Fund
Normal Dividend, Payout ₹226.244
↑ 1.96 15.13 % 1.31 % 24.55 % 17.12 % UTI Healthcare Fund
Normal Dividend, Reinvestment ₹226.244
↑ 1.96 15.13 % 1.31 % 24.55 % 17.12 % Data as on 10 Oct 25